FDA
-
-
-
-
-
-
-
VivoSim Labs plans rat liver model to pair with human platform
-
-
-
-
-
-
-
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
-
-
-
-
-
-
-
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
-
-
-
-
-
-
-
VivoSim names Raghunathan VP of global sales
-
-
-
-
-
-
-
VivoSim Labs names Tony Lialin as chief commercial officer
-
-
-
-
-
335,988 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


